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ABSTRACT 
Recent studies have shown that Sca-1
+
 (stem cell antigen-1) stem/progenitor cells within 
blood vessel walls may contribute to neointima formation, but the mechanism behind their 
recruitment has not been explored. In this work Sca-1
+
 progenitor cells were cultivated from 
mouse vein graft tissue and found to exhibit increased migration when co-cultured with 
SMCs or when treated with SMC-derived conditioned medium. This migration was 
associated with elevated levels of chemokines, CCL2 (chemokine (C-C motif) ligand 2) and 
CXCL1 (chemokine (C-X-C motif) ligand 1), and their corresponding receptors on Sca-1
+
 
progenitors, CCR2 (chemokine (C-C motif) receptor 2) and CXCR2 (chemokine (C-X-C 
motif) receptor 2), which were also up-regulated following SMC conditioned medium 
treatment. Knockdown of either receptor in Sca-1
+
 progenitors significantly inhibited cell 
migration. The GTPases Cdc42 and Rac1 were activated by both CCL2 and CXCL1 
stimulation and p38 phosphorylation was increased. However, only Rac1 inhibition 
significantly reduced migration and p38 phosphorylation. After Sca-1
+
 progenitors labeled 
with GFP were applied to the adventitial side of wire-injured mouse femoral arteries, a large 
proportion of GFP-Sca-1
+
-cells were observed in neointimal lesions, and a marked increase 
in neointimal lesion formation was seen 1 week post-operation. Interestingly, Sca-1
+
 
progenitor migration from the adventitia to the neointima was abrogated and neointima 
formation diminished in a wire injury model using CCL2
-/-
 mice. These findings suggest 
vascular stem/progenitor cell migration from the adventitia to the neointima can be induced 
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by SMC release of chemokines which act via CCR2/Rac1/p38 and CXCR2/Rac1/p38 
signaling pathways.   
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INTRODUCTION 
 
Smooth muscle cells (SMCs) are well established as a key cell type that can contribute to the 
pathology of vascular diseases such as atherosclerosis and post-angioplasty restenosis[1-3]. 
Increasing evidence suggests that during vascular injury, SMCs in the media layer of the 
vessel undergo dedifferentiation from a quiescent/contractile phenotype to an active/synthetic 
phenotype and contribute to neointima formation through increased cell proliferation and 
migration[4, 5]. During this process, SMCs secrete a variety of chemokines such as 
chemokine (C-C motif) ligand 2 (CCL2) and (C-X-C motif) ligand 1 (CXCL1)[6]. These 
chemokines are largely responsible for recruitment of inflammatory cells[7, 8]. For example, 
after vascular injury, CCL2 is released by SMCs in a hypercholesterolemia mouse model and 
simultaneously chemokine (C-C motif) receptor 2 (CCR2) is up-regulated on monocytes, 
which leads to over-recruitment of leukocytes to lesion sites[9, 10]. In ApoE
-/- 
mice CXCL1 
presented by the lesion-prone endothelium triggers monocyte recruitment in a process 
dependent on α4β1 integrin[11]. In the late stage of atherosclerotic lesion development, 
CXCL1 is also important for macrophage accumulation via leukocyte expression of 
chemokine (C-C motif) receptor 2 (CXCR2)[12]. Additionally, neutralization of CXCL1 
reduces endothelial chemotaxis in vitro and delays endothelial recovery after arterial injury in 
vivo in a CXCR2-dependent manner[13]. However, little is known about the roles of CCL2 
and CXCL1 secreted by SMCs in recruitment of other cell types, e.g. vascular resident 
stem/progenitor cells, into the intima in response to injury. 
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Recently, studies from several laboratories have identified the presence of a range of 
multipotent and lineage-restricted stem/progenitor cells in the adventitia of the vessel wall. 
These cells possess high potential to differentiate into many cell lineages, including 
endothelial and smooth muscle cells, adipocytes and osteoblasts[14-16]. Progenitor cells 
residing in the adventitia are positive for the stem/progenitor markers stem cell antigen-1 
(Sca-1) and c-kit[17]. In our recent studies, we have shown that Sca-1
+
 cells can migrate 
towards sirolimus, a drug used to coat stents[18], and differentiate into SMCs in vitro and in 
an ex vivo model of decellularized vessels[17, 19]. However, it is unknown whether 
chemokines released from SMCs in response to injury play a role in attracting vascular stem 
cells. The aims of this study were to investigate whether local SMC-released chemokines can 
induce adventitial-derived resident progenitor cell migration and to elucidate the mechanism 
behind progenitor cell promotion of neointima formation after vessel injury. In the present 
report, we demonstrate that SMCs can induce Sca-1
+
 progenitor cell migration upon the 
release of CXCL1 and CCL2, which in turn activate the Rac1/p38 MAPK signaling pathways 
via the receptors CXCR2 and CCR2 respectively. Importantly, we demonstrate that 
CCL2-deficent mice display reduced Sca-1
+
 cell migration and neointima formation in 
response to vessel injury. 
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MATERIALS AND METHODS 
Mouse vascular progenitor cell culture  
The vena cava of a C57BL/6J mouse was isografted to the carotid artery of an isogenic 
mouse or GFP C57BL/6J mouse. After 2 weeks graft tissues were harvested and explanted in 
gelatin-coated flasks. Culture was in complete stem cell culture medium. 
 
Cell Sorting 
Vascular progenitor cells (VPCs) were sorted with anti-Sca-1 immunomagnetic microbeads 
and then selected using a magnetic cell separator. Sca-1
+
 vascular progenitor cell populations 
were expanded for up to 5 population doublings. 
 
Statistical Analysis 
Data for this study are presented as the mean ± standard error of the mean (S.E.M.) of at least 
three separate experiments. Analysis was performed using Graphpad Prism V.6 (GraphPad 
Software, San Diego CA) using analysis of variance (one way ANOVA) followed by 
Dunnett’s multiple comparison tests. Significance was considered when p<0.05. 
 
Detailed Methods are included in the Online Data Supplemental.  
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RESULTS 
Characterization of vascular stem/progenitor cells (VPCs) 
Previously published works by our group identified a population of progenitor cells within 
pathological vessels from a mouse vein graft model[19, 20]. As in this previous work, 2 
weeks after implantation of vein grafts, a large heterogeneous population of cells was found 
to migrate from the adventitia of vessels and contributed to neointima formation[17]. Cells 
were isolated from the adventitia and used to derive clones of single cells. 
Immunofluorescent staining showed that cells from this cloned population express progenitor 
cell marker Sca-1 (stem cell antigen-1) (Supplemental Figure 1A, B), but express very few 
smooth muscle cell or endothelial cell markers (Supplemental Figure 1C, D). In order to 
purify a larger pool of Sca-1
+
 progenitor cells from the initially heterogeneous adventitial 
population anti-Sca-1 immunomagnetic microbeads were used. Approximately 15% of total 
cells collected using this method was identified as Sca-1
+
 progenitor cells after sorting (Data 
not shown). Sca-1
+ 
cells derived from clones and a mixed population of Sca-1
+
 progenitor 
cells derived by magnetic sorting were further characterized by a qPCR array showing gene 
expression of chemokines and chemokine receptors, further details are described in the 
following results. Our hypothesis is that Sca-1
+
 progenitors may contribute to the pathology 
of atherosclerosis, potentially via their expression of chemokines and receptors. 
 
SMC-conditioned medium induced VPC migration 
To investigate whether SMCs influence the migratory capacity of vascular progenitor cells, a 
transwell migration assay was performed. Increasing numbers of SMCs were seeded on the 
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base of the lower chamber while fixed numbers of VPCs were seeded on the 8.0 µm pore 
membrane of the upper chamber. Using an increasing ratio of VPCs to SMCs (from 1:0 to 
1:5), and allowing an overnight incubation, we found that the migration of VPCs increased as 
the number of SMCs increased and this reached its peak when the VPC:SMC ratio was 1:2 
(Figure 1A). Next, SMC-conditioned medium was collected from SMC cultured overnight in 
serum free medium and used for migration assays. Addition of SMC-conditioned medium 
consistently stimulated VPC migration in both transwell and wound healing assays, when 
compared to serum free medium. (Figure 1B, C).  
 
Time lapse microscopy was used to track the speed and the persistence of single progenitor 
cells during their migration when treated with SMC conditioned medium in an overnight 
incubation. These results showed that SMC-conditioned medium augmented directional 
persistence of VPC migration, while migrational velocity remained unaltered between the 
treatments (Figure 1D, E, F and supplemental online Video 1 (control)，supplemental online 
Video 2 (SMC conditioned medium)). Use of a BrdU cell proliferation assay confirmed that 
this effect was not due to proliferation (Supplemental Figure 2A). qPCR analysis revealed 
that the mRNA levels of SMC markers (calponin and α-SMA) and endothelial marker 
(CD31) in VPCs were not significantly changed during the experiment (Supplemental Figure 
2B, C, D). VPCs also maintained progenitor characteristics, as the progenitor marker Sca-1 
was not significantly changed when compared to the control (Supplemental Figure 2E). 
Additionally, immunofluorescence staining for paxillin, vinculin and phosphorylated FAK 
showed that relocation of cytoskeleton-related proteins was increased (Supplemental Figure 
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3A). Taken together, the above results support the notion that both co-culture with SMC and 
SMC-derived conditioned medium can induce VPC migration.  
 
SMC-released CCL2 and CXCL1 induced VPC migration  
To further investigate which mediators released by SMCs were responsible for the 
conditioned medium induced VPC migration, we performed a chemokine multi-ELISA array. 
This revealed that CXCL1 and CCL2 levels were markedly increased in SMC-conditioned 
medium when compared to serum free medium (Figure 2A). Murine CCL2 or CXCL1 
Quantikine kits established that the amounts of CCL2 and CXCL1 in the conditioned medium 
were 4.63±1.29 ng/ml and CXCL1 3.08±0.99 ng/ml, respectively (Figure 2B, C). While the 
level of CCL5 was also up-regulated in comparison to the control, subsequent transwell 
migration assays found that it did not affect VPC migration (Supplemental Figure 4A, B). To 
confirm the roles of CCL2 and CXCL1 in mediating VPC migration, we performed transwell 
and wound healing assays using exogenous mouse recombinant CCL2 and CXCL1 proteins, 
respectively. VPC migration was enhanced by CCL2 and CXCL1 treatment and peaked at 5 
ng/ml (a 6 fold increase in CCL2 and a 2 fold increase in CXCL1 treated cells) (Figure 2D, 
E). These were similar concentrations of CCL2 and CXCL1 to those measured in 
SMC-derived conditioned medium. That a 5ng/ml CCL2 or CXCL1 treatment enhanced VPC 
migration was confirmed by wound healing assay (Figure 2F, G). Silencing of CCL2 or 
CXCL1 in the SMCs using siRNAs resulted in significant down-regulation of CCL2 and 
CXCL1 at both the mRNA and protein levels (Figure 2H, I, J, K). Importantly, CCL2 or 
CXCL1 depleted SMCs failed to stimulate VPC migration in transwell assays (Figure 2L, 
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M). To further investigate the relationship between CCL2 and CXCL1 in SMC conditioned 
medium induced VPC migration，CCL2 and/or CXCL1 concentrations were depleted using 
their corresponding neutralizing antibodies. The antibodies were found to be effective and 
selective as they significantly reduced the availability of their target chemokine while they 
had no effect on the other chemokine studied. Depletion of either CCL2 or CXCL1 did not 
result in a compensatory release of the other chemokine and there appeared to be no 
interactions between the two antibodies (supplemental Figure 5A, B). Having confirmed the 
effectiveness of the neutralizing antibodies they were used to study the role of CCL2 and 
CXCL1 in VPC migration.  Depletion of either CCL2 or CXCL1 in SMC conditioned 
medium inhibited migration of VPCs by nearly 50%.  However, simultaneous depletion of 
CCL2 and CXCL1 in SMC conditioned medium did not further reduce this migration level 
(supplemental Figure 5C, D).  Finally, incubation with various concentrations of CCL2 or 
CXCL1 did not stimulate VPCs autocrine production of the other chemokine (supplemental 
Figure 5E, F).  Taken together, these results suggest that though CCL2 and CXCL1 derived 
from SMCs play an important role in the induction of VPC migration, their interaction is 
neither cumulative nor redundant but both are required for migration to be induced.  
 
 
VPC migration is mediated by CCR2 and CXCR2 
Each chemokine needs to interact with its corresponding receptor in order to exert an effect. 
We investigated the chemokine receptor profile of VPCs by performing a qPCR-array of a 
mixed population of Sca-1
+
 progenitor cells derived by magnetic sorting and Sca-1
+
cells 
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derived from a clone. We demonstrated that VPCs possess a variety of chemokine receptors 
(Figure 3A, Supplemental Table 2) and importantly, CCR2 and CXCR2, the corresponding 
receptors of CCL2 and CXCL1. Both mRNA and protein level expression of these receptors 
was significantly up-regulated after treatment with SMC conditioned medium (Figure 3B, C, 
D, E). To silence CCR2 and CXCR2 in VPCs at the gene level, VPCs were infected with 
CCR2 or CXCR2 lentiviral shRNA while a null shRNA was also introduced into VPCs as a 
control. The cells were selected for 4-5 days using neomycin and maintained in complete 
culture medium. Subsequent transwell migration experiments with CCR2 or CXCR2 
silencing resulted in a significant decrease in VPC migration (Figure 3F). In addition, 
pretreatment with antagonists of CCR2 or CXCR2 led to down-regulation of VPC migration 
in response to chemokines (Supplemental Figure 6A, B). These findings suggest that CCL2 
and CXCL1 released from SMCs induce VPC migration via interaction with their 
corresponding receptors CCR2 and CXCR2. 
 
CCL2 and CXCL1 induced VPCs migration through the Rac1-p38 pathways 
The Rho GTPase family members Rac1 and Cdc42 have been implicated as important 
regulators of cell migration[21]. To investigate whether Cdc42 and Rac1 are involved in VPC 
migration, we measured the level of GTP-Cdc42 and GTP-Rac1 using pull down assays. 
Stimulation of VPCs with mouse recombinant CCL2 or CXCL1 resulted in both Cdc42 and 
Rac1 activation (Figure 4A, B). Treatment with either ML141 (an inhibitor of Cdc42) or 
NSC23766 (an inhibitor of Rac1) resulted in a significant reduction in VPC migration 
induced by CCL2 and CXCL1 as compared to control (Figure 4C, D).  
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p38 MAPK has been identified as the down-stream signal transducer of active forms of 
Cdc42 and Rac1 and the p38 signaling pathway can induce rearrangements of the 
cytoskeleton that regulate cell migration[22, 23]. A time course using western blotting 
analysis showed p38 phosphorylation occurred in VPCs after treatment with SMC 
conditioned medium for 20 minutes (Figure 4E). p38 phosphorylation was up-regulated in 
response to mouse recombinant CCL2 and CXCL1 treatment (Figure 4F), and suppressed in 
response to conditioned medium derived from CCL2 siRNA or CXCL1 siRNA depleted 
SMCs (Figure 4G). p38 phosphorylation was also suppressed in VPCs where CCR2 or 
CXCR2 had been knocked down using the corresponding shRNA (Figure 4H). Pretreatment 
of VPCs with CCR2 or CXCR2 antagonists consistently reduced the p38 phosphorylation 
(Supplemental Figure 6C, D). Importantly, p38 phosphorylation was significantly reduced in 
VPCs pretreated with NSC23766 but not ML141 (Figure 4I, J). Finally, migration of VPCs 
was reduced in the presence of SB203580 (an inhibitor of the p38-MAPK signaling pathway) 
(Figure 4K). These indicate Rac1 regulates CCL2 and CXCL1 induced VPC migration via 
the p38 signaling pathway. RhoA, as another important small GTPase has also been reported 
to regulate the cell migration process[21], however, pretreatment of VPCs with C3 
transferase (an inhibitor of RhoA), did not alter VPC migration or p38 phosphorylation 
(Supplemental Figure 7). We therefore conclude that CCL2 and CXCL1 induce VPC 
migration by activating GTPase Rac1 and p38 signaling pathways.  
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Lack of CCL2 inhibits Sca-1
+
 cell migration and neointima formation 
SMCs can be described as activated and switched into the synthetic phenotype when they are 
cultured in vitro[24] and under these conditions they constitutively release CCL2 and 
CXCL1. To study chemokine release in in vivo conditions, a mouse femoral artery wire 
injury model was used to assess whether native SMCs only produce chemokines which 
attract VPC migration after cell injury. Co-immunofluorescence staining of α-SMA and 
CCL2 or CXCL1 showed that in intact vessels, SMCs are quiescent and do not produce 
CCL2 or CXCL1. However, once SMCs are injured they release increasing levels of CCL2 
and CXCL1 (both at a short time point (6 hours) and a long time point (2 weeks) 
(Supplemental Figure 8). These chemokines could be potent and persistent attractants for 
VPC migration. To verify this, GFP-Sca-1
+
-VPCs, additionally labeled using a Qtracker
®
 655 
Cell Labeling Kit, were seeded on the adventitia of vessels which were injured. En face 
confocal microscopy revealed that 72 hours after injury the number of migrated cells found 
on the intimal side of the vessel wall was significantly lower in CCL2
-/-
 mice when compared 
to WT mice (Figure 5A, Supplemental Figure 10A). CCL2
-/-
 mice were identified by 
genotyping mice and measuring CCL2 levels in peripheral blood (Supplemental Figure 9A, 
B). Quantification based on either GFP-Sca-1
+
-VPCs or Qtracker
®
 showed similar results 
(Figure 5B, Supplemental Figure 10B). Sca-1 immunofluorescence staining in sections of 
injured arteries 2 weeks post injury, showed that GFP-Sca-1
+
-VPCs remained Sca-1 positive 
after 2 weeks in vivo but that fewer migrated into the intimal side to contribute to neointima 
formation in CCL2
-/-
 mice compared to the WT mice (Figure 5C, D, E).  These results 
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suggest a role for CCL2 in VPC migration from the adventitia to the intima where they may 
contribute to neointima formation. 
 
To further investigate the role of CCL2 in VPC neointima formation, wire-injured femoral 
arteries were seeded with VPCs or PBS in the adventitia. HE stained sections showed 
neointima formation in the vessel at 1 or 2 weeks after wire injury (Figure 6A, B). 
Quantification of the data indicated that neointimal lesions were significantly increased in 
vessels seeded with VPCs. In the 2 week post injury group, the difference in ratio of 
neointima to media with VPCs or PBS was higher than that in the 1 week group. However, 
neointimal lesions in CCL2
-/-
 mice were decreased in vessels with either VPCs seeded in the 
adventitia or PBS. There is a significant reduction in neointimal lesions area of vessels with 
VPC seeding in CCL2
-/-
 mice when compared to the WT mice at 2 weeks.   
 
To characterize cells contributing to neointima formation, immunofluorescence staining of 
α-SMA and Sca-1 was used, which showed that the cells in the neointima of PBS treated 
vessels were approximately 70% α-SMA+ and 10% Sca-1+ 2 weeks after injury 
(Supplemental Figure 11). Staining of α-SMA and CCR2 in Figure 6 revealed that cell 
numbers in neointima of VPC seeded vessels were increased, though fewer were α-SMA+. 
These results indicate that in the PBS treated vessels, most cells contributing to neointima 
formation are α-SMA+.  These cells are either from media SMC migration and proliferation 
or from progenitor cell differentiation. When Sca-1
+
 VPC were seeded in the adventitia, the 
ratio of α-SMA+ cells was significantly decreased which implies that VPCs possess high 
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potential to migrate and proliferate. Over a short time most cells maintained their progenitor 
cell characteristics, though several had differentiated into SMCs (Figure 6C, E). CCR2 was 
more highly expressed on the cells in the neointima of VPC-seeded vessels (Figure 6D, F). 
These data suggest that VPCs applied to the adventitia significantly increase neointima 
formation after vessel injury, largely through their migration though with a lesser effect due 
to their differentiation into SMCs. Furthermore, lack of CCL2 markedly inhibits the effect of 
VPCs on neointima formation.  
 
Role of CCL2 released from non-bone marrow tissue  
CCL2 is not only released from bone marrow cells but also from SMCs, endothelial cells and 
other tissues[9, 25]. To investigate which source of CCL2 plays the most important role in 
neointima formation due to VPC migration chimeric mouse models were created. Wild-type 
bone marrow was transplanted into an irradiated CCL2
-/-
 mouse to form a CCL2 chimera. 
Conversely, a wild-type chimeric mouse model was prepared by transplanting CCL2
-/-
 mouse 
bone marrow cells into an irradiated wild-type mouse. The levels of CCL2 in serum of 
peripheral blood were measured using a murine CCL2 ELISA kit. In the wild-type chimeric 
mouse model, the level of CCL2 in peripheral blood was increased despite transplantation 
with CCL2
-/-
 bone marrow when compared to a non-transplanted wild-type mouse control, 
indicating that CCL2 is mostly released from non-bone marrow tissue. In contrast, the level 
of CCL2 was increased in CCL2
-/-
 mice with transplanted wild-type bone marrow cells, but to 
a much lesser extent, indicating that only a small proportion of CCL2 is released from bone 
marrow derived cells (Figure 7A). Data from HE stained sections showed that neointima 
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lesion area correlated with the CCL2 level in blood (Figure 7B, C). These results support the 
observations that CCL2 induced VPC migration contributes to neointima formation. 
 
CXCL1 plays a role in Sca-1 positive cell migration in vivo 
Previous studies have demonstrated that CXCL1 can induce endothelial cell migration and 
tube formation in vitro[26] and also acts as an angiogenic factor to promote tumor 
growth[27]. To further investigate the role of CXCL1 in induction of VPC migration in vivo, 
VPCs were mixed with matrigel containing either PBS or mouse recombinant CXCL1 and 
injected subcutaneously. After 2 weeks, the number of cells that migrated into the matrigel 
was significantly increased in the CXCL1 group when compared to PBS controls 
(Supplemental Figure 12A). Immunofluorescence staining of Sca-1, CD31 and α-SMA 
showed that most of the migrated cells in the matrigel plug were Sca-1 positive, whilst some 
were CD31 positive, and only very few were α-SMA positive (Supplemental Figure 12B). In 
addition, CXCL1 or control siRNA within the pluronic gel was delivered to the adventitial 
side of wire injured vessels to assess the effect of local CXCL1 knockdown on Sca-1
+
 VPC 
migration in vivo. Successful in vivo knockdown of CXCL1 mRNA level in injured femoral 
arteries was confirmed after 6 days using real time quantitative PCR (Supplemental Figure 
13A). Furthermore, En face confocal microscopy revealed that 72 hours after seeding 
GFP-Sca-1
+
VPC in the adventitia, the number of migrated cells found on the intimal side of 
the vessel wall was lower in CXCL1 siRNA treated vessels compared to the control siRNA 
(supplemental Figure 13B). These results indicate the important role of CXCL1 in Sca-1
+
 
cells migration in vivo.  
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DISCUSSION 
Restenosis is still the main complication that exacerbates the outcome of coronary artery 
disease after percutaneous coronary intervention[28-30]. Smooth muscle cell proliferation 
and migration are suggested to be important factors in development of neointimal hyperplasia 
and restenosis[31]. In the present study, we identify a new mechanism of smooth muscle 
accumulation in neointimal lesions after vascular injury, in which vascular stem/progenitor 
cells migrate from the adventitia to the intima. We demonstrate that proliferating SMCs can 
release several chemokines, including CXCL1 and CCL2, which have a role in attracting 
these vascular progenitors. Single cell tracking experiments indicate that cells are migrate 
directionally and efficiently but not randomly. Importantly, perivascular application of 
GFP-Sca-1
+
-VPC to injured arteries significantly enhanced neointimal lesion formation via 
progenitor migration. This effect is diminished by CCL2 knockout. We provide the first 
evidence that the SMC-produced chemokine CCL2 is crucial for vascular progenitor 
migration from the adventitia to the intima where these cells contribute to lesion formation.  
 
After endothelial injury, an inflammatory response occurs in the vessel wall, and chemokines 
are released by both mononuclear cells and SMCs[32, 33]. Using multiple chemokine ELISA 
we demonstrated that several chemokines were up-regulated in cultured SMCs and amongst 
them, CXCL1, CCL2 and CCL5 were secreted at the highest levels. To further confirm the 
effects of these chemokines, we stimulated stem cells with exogenous mouse recombinant 
proteins and found that CCL2 and CXCL1 significantly induced vascular progenitor 
migration. Previous studies have reported that CCL5 mediates trafficking and homing of T 
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cells, monocytes, basophils and eosinophils[34-37]. However, it does not appear to play such 
a role in induction of progenitor migration, indicating that vascular stem cells may selectively 
or specifically respond to certain chemokines. 
 
Chemokine receptors are expressed on many different cell types, such as granulocytes, 
monocytes, mast cells, T cells, and endothelial cells[38, 39], but no prior study has shown the 
presence or absence of chemokine receptors on vascular progenitors. We used a qPCR array 
to profile the expression of chemokines, cytokines, and their receptors in different vessel wall 
cell lines. The results showed the presence of most cytokines and chemokine receptors in a 
mixed population of Sca-1
+
 progenitor cells derived by magnetic sorting and one clone of 
Sca-1
+
 progenitor cells and although SMCs display a higher expression level of different 
chemokine receptors. This distinct chemokine receptor profile marks a distinction between 
mature SMCs and progenitors. Expression of CCL2 and CXCL1 was much higher on SMCs 
compared to other cells, which was similar to our finding at the protein level of CCL2 and 
CXCL1 in SMCs as measured in the ELISA array. As many reports have demonstrated, 
CCL2/CCR2 and CXCL1/CXCR2 signal transduction mediates recruitment of neutrophils, 
monocytes or macrophages into inflammatory sites during progression of different kinds of 
disease[12, 40-43].  In our study, we found that both CCR2 and CXCR2 were up-regulated 
on VPCs after treatment with SMC-derived chemokines. The ability of VPCs to migrate after 
CCR2 and CXCR2 genes were permanently silenced by shRNA was significantly reduced. 
This indicates that SMC-released CCL2 and CXCL1 activate their corresponding receptors 
on vascular stem/progenitor cells. 
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In order to elucidate the mechanism of cell migration we studied the role of the Rho GTPase 
family. Rac1, Cdc42 and RhoA, as the main Rho GTPase family members, regulate the 
formation of lamellipodia, filipodia and focal adhesions, respectively[44]. In the present 
study, we found both Cdc42 and Rac1 in VPCs were activated by CCL2 and CXCL1 and 
inhibition of either Cdc42 or Rac1 impaired VPC migration in response to CCL2 or CXCL1. 
Cytokines such as IL-4 and TNF-α can activate stress-activated pathways leading to 
phosphorylation of p38 MAPK which is dependent on Rac1 and Cdc42[45, 46]. In our study, 
p38 phosphorylation was up-regulated in response to mouse recombinant CCL2/CXCL1, and 
p38 phosphorylation was suppressed by CCL2/CXCL1 knockdown or CCR2/CXCR2 
inhibition. These results suggest that progenitor migration is induced through a p38 MAPK 
signaling pathway. Importantly, we also found that p38 phosphorylation was markedly 
down-regulated by Rac1 inhibition but not inhibition of Cdc42 or RhoA, suggesting that 
progenitor migration is induced via a Rac1/p38 signaling pathway. Although the migration 
assay showed the participation of Cdc42 in SMC induced progenitor migration, it may 
through an as yet unidentified signaling pathway.  
 
As the above results show that CCL2 and CXCL1 contribute to VPC migration equally, we 
wanted to further investigate possible interactions between the two chemokines. Depletion of 
each chemokine was found to partially inhibit VPCs migration, but treatment with each 
chemokine individually failed to stimulate VPCs to release the other. After loss of one 
chemokine, the induction of VPCs migration is not compensated by the other chemokine. 
Simultaneous depletion of both chemokines did not further inhibit VPC migration when 
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compared to inhibition of a single chemokine. The effects of CCL2 and CXCL1 in the 
mediation of VPCs migration were found to be neither cumulative nor redundant. However, 
there may also be additional factors in SMC conditioned medium which play a role in 
inducing VPC migration, as migration was not completely abolished on depletion of both 
chemokines. We have shown that both chemokines induce VPC migration through the 
Rac1/p38 signaling pathway but act through their own receptors. Previous studies[47, 48] 
have shown that chemokine receptors can form co-receptors to mediate their effects, thus 
further studies need to be performed to determine whether CCR2 and CXCR2 form a 
co-receptor to induce VPC migration. 
  
Reports using different animal models have shown that CCL2 plays an important role in 
neointimal hyperplasia[49-51], for example CCL2 enhances SMC migration, proliferation 
and invasion to remodel vessels[52, 53]. VPCs have also previously been identified as 
playing a role in neointima formation[17, 19]. In the present study, we demonstrated that 
migrating progenitors are an important cellular component of CCL2 mediated neointima 
formation. We found CCL2 not only enhanced VPC migration from the adventitia to the 
intima in a short time period but also accelerated neointima formation by inducing VPC 
migration. We also identified that the majority of cells contributing to neointima formation 
are not smooth muscle cell marker positive but express a stem cell marker (Sca-1), which 
indicates that though some VPCs participate in neointima formation and differentitate into 
SMCs, most of them retain progenitor cell characteristics as they migrate into the neointima.  
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The expression of CCR2 in neointimal cells suggests that the participtation of VPCs in 
neointima formation may be dependent on CCL2-driven recruitment. Vande et al 
demonstrated the main source of CCL2 is bone marrow-derived monocytes[54]. In our study, 
through use of chimeric mouse models, we found that after bone marrow transplant, CCL2 
can be detected in the peripheral blood of a CCL2
-/-
 chimeric mouse (bone marrow was from 
WT mouse), where it was originially undetectable. This confirms the findings of previous 
studies[54]. However, in a WT chimeric mouse (bone marrow was from CCL2
-/-
 mouse), the 
levels of CCL2 were markedly up-regulated and showed an even higher increase compared to 
the CCL2
-/-
 chimeric mouse. This indicates that CCL2 from non-bone marrow tissues (e.g. 
SMC) contributes more to the global CCL2 levels in the peripheral blood than bone marrow. 
Quantitative data from neointimal lesions further confirms that CCL2 from non-bone marrow 
tissues-induces progenitor migration which contributes to neointima formation. Taken 
together, CCL2 released from non-bone marrow tissues (e.g. SMC) accelerates neointima 
formation through induction of progenitor migration from adventitia to neointima. 
 
It was believed that neointimal formation in response to endothelial injury was mainly due to 
cell accumulation via recruiting inflammatory cells[55, 56] and SMCs[57, 58] from the 
media. In this study, we utilised an accelerated model of in vivo neointima formation by 
inducing endothelial injury. From the data generated in non-VPC seeded groups, we found 
that during the short time period of 1-2 weeks very few cells contributed to the spontaneous 
development of neointimal lesions.  In contrast, an obvious neointima was found in VPC 
seeded groups, which suggested that the neointima formation is largely generated by VPCs 
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migration in the early stage of the model. These findings have two implications. First, the 
cells accumulating in neointimal lesions may be derived from migration/proliferation of 
vascular stem cells, which can differentiate into SMC-like cells, although mononuclear cells 
and medial SMCs contribute to the process. To obtain quantative data on how many cells in 
neointimal lesions are derived from progenitor cells, lineage tracing for progenitor cells in 
animal models would be essential. Secondly, a new treatment strategy for restenosis could be 
considered. Current treatments used in clinical are based on inhibition of cell proliferation[59, 
60], e.g. sirolimus. A recent report from our group suggests that sirolimus can enhance 
vascular stem/progenitor cell differentiation into SMCs, but inhibits endothelial 
differentiation[18]. Our current findings that large numbers of stem/progenitor cells are 
recruited to the intima in response to CCL2 and CXCL1 provide a potential to direct cell 
differentiation into the endothelial lineage. In other words, a high number of stem cells exist 
during neointima formation, which could differentiate into endothelial cells if a new drug 
coated stent could harness their potential and directed them specifically.  
 
SUMMARY 
Taken together, these results may provide crucial answers as to why restenosis and delayed 
re-endothelialization persist after angioplasty and stenting, which may be fundamental for 
developing new drugs that can improve the long-term outcome of patients. 
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Figure Legends 
Figure 1. SMC conditioned medium can induce VPCs migration. A. Chemotaxis of 
vascular progenitor cells (5×10
4 
cells/well) across 8.0 μm transwells toward an increasing 
number of SMCs after 18 hours was documented after 0.1% crystal violet staining. Serum 
free culture medium was used as control for all migration experiments, n=5. Scale bars, 
100µm. B, C. Migration of vascular progenitor cells in response to SMC conditioned 
medium. Chemotaxis index was defined by average of 9 fields of view and was presented as 
fold increase compared to the control, n=5. Scale bars, 100µm. D, E, F Vascular progenitor 
cells were incubated with or without SMC conditioned medium for 20 hours. Time lapse 
microscopy was performed to observe single cell movement. Trajectory plots of migrating 
VPC are shown in (D), 100 tracked single cells in each group are displayed. Quantification 
analysis of the speed (E) and persistence (F) of VPC were performed in 3 independent 
experiments. All graphs are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. ns, 
P>0.05. ctrl, control, serum free medium. CM, SMC conditioned medium. 
 
Figure 2. CCL2 and CXCL1 released from SMC conditioned medium induced VPCs 
migration. A. The identification of chemokines in SMC conditioned medium using a 
Chemokine Multiarray ELISA kit. The graph indicates the absorbance of each chemokine at 
450nm. n=3. B, C. The concentrations of CCL2 and CXCL1 in SMC conditioned medium 
were quantified by the murine CCL2 or CXCL1 Quantikine ELISA kit. n=3. D, E. Changes 
in vascular progenitor cells migration in response to a gradient of CCL2 or CXCL1 in serum 
free culture medium were evaluated using a transwell assay. n=5. Scale bars, 50µm. F, G. 
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Wound healing assay was performed on vascular progenitor cells treated with CCL2 (5ng/ml), 
CXCL1 (5ng/ml) or vehicle control. Graphs are shown as fold increase relative to controls. 
Scale bars, 100µm. SMCs were transfected either with control noncoding small interfering 
RNA (siRNA), CCL2 siRNA (300nM) or CXCL1 siRNA (100nM) to knockdown 
corresponding mRNA. The real-time quantitative PCR and Quantikine ELISA kit showed the 
folds decrease in mRNA (H, J) and protein (I, K) levels in CCL2 or CXCL1 siRNA 
transfected SMCs and their conditioned medium respectively. n=3. L, M. Transwell assay 
was performed on vascular progenitor cells migrating towards SMC (transfected either with 
noncoding siRNA, CCL2 siRNA or CXCL1 siRNA) conditioned medium. n=5. Scale bars, 
50µm. All graphs are shown as mean ± SEM. **p<0.01, ***p<0.001. NCsi, noncoding 
siRNA. siCCL2, CCL2 siRNA. siCXCL1, CXCL1 siRNA. ctrl, control, serum free medium. 
CM, SMC conditioned medium. 
 
Figure 3. SMC conditioned medium induced VPC migration by up-regulating 
expression of CCR2 and CXCR2. A. Cluster grams show the expression of 84 chemokine 
receptors, chemokine and other chemotactic cytokines on the untreated smooth muscle cells, 
clones and Sca-1
+
 VPCs individually. A row in the cluster represents a cell line, and relative 
level of expression for a gene is arranged in column. The magnitude of gene expression 
increases from green to red. The dendrogram of the different cell lines clustering is displayed 
aside and describes the degree of relatedness among different cell lines. Quantification was 
performed with three different batches of each cell line. The vascular progenitor cells were 
treated with or without SMC conditioned medium for 18 hours, untreated cells served as 
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controls. n=3. The mRNA (B, D) and cell-surface protein (C, E) expression of CCR2 or 
CXCR2 was confirmed using real-time quantitative PCR and flow cytometry. n=3. F. 
Vascular progenitor cells were infected with lentiviral short hairpin RNA (shRNA) 
(noncoding shRNA, CCR2 shRNA or CXCR2 shRNA) for ablation of CCR2 or CXCR2 
before migration toward SMC conditioned medium. The noncoding shRNA served as the 
control. n=3. Scale bars, 100µm. All graphs are shown as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001. NCsh, noncoding shRNA. shCCR2, CCR2 shRNA. shCXCR2, CXCR2 shRNA. 
ctrl, control, serum free medium. CM, SMC conditioned medium. 
 
Figure 4. SMC induces VPCs migration via activated GTPase Cdc42 and Rac1 and p38 
signaling pathway. A, B. Pull down assays were performed on VPCs treated with either 
CCL2 or CXCL1 for 5 minutes. The transwell assay was performed on VPCs that were 
pretreated with either vehicle, DMSO or ML141 (20 µM) (C), NSC23766 (50 µM) (D), 
SB203580 (10µM) (K) for 1 hour before migration toward either SMC conditioned medium 
or recombinant CCL2, CXCL1. Scale bars, 100µm. The quantification of transwell assay 
shows as the fold of changes compared with cell migrated toward each treatment pre-treated 
with vehicle or DMSO. Western blotting was performed on SMC conditioned medium (E), 
CCL2 or CXCL1 (F), SMCs (transfected with CCL2 siRNA or CXCL1 siRNA) conditioned 
medium (G)-treated VPCs for the detection of p-p38 and t-p38. H. Cell lysates from CCR2 
shRNA or CXCR2 shRNA transfected VPCs cultured in the SMC conditioned medium were 
harvested for the detection of the p-p38 and t-p38. Untreated cells served as the controls. I, J. 
After pre-treated with ML141, NSC23766 for 1 hour, VPC were stimulated by SMC 
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conditioned medium or CCL2, CXCL1 before cell lysates were harvested for detection of the 
p-p38 and t-p38. All the blots shown are representative of 3 separate experiments. All graphs 
are shown as mean ± SEM. n=3. *p<0.05, **p<0.01, ***p<0.001. NCsi, noncoding siRNA. 
siCCL2, CCL2 siRNA. siCXCL1, CXCL1 siRNA. NCsh, noncoding shRNA. shCCR2, 
CCR2 shRNA. shCXCR2, CXCR2 shRNA. ctrl, control, serum free medium. CM, SMC 
conditioned medium. DMSO, dimethyl sulfoxide. vehicle, sterile distilled water. p-p38, 
phosphorylated p38. t-p38, total p38. 
 
 
Figure 5. Lack of CCL2 inhibits Sca-1
+
 cell migration in vivo. A. Using a mouse femoral 
artery wire injury model, GFP-Sca-1
+
 vascular progenitor cells (GFP-Sca-1
+
-VPC) (1x10
6
) 
were seeded in the adventitia of each injured vessel. En face staining shows the cells were 
migrated to the intima side of the vessels 72hrs post injury of WT and CCL2
-/-
 mice. Scale 
bars, 25µm. B. The percentage of GFP-Sca-1
+
-VPC within respective DAPI
+
 populations in 
each view was quantified. C. The femoral arteries sections from WT and CCL2
-/-
 mice 2 
weeks post injury were prepared for immunofluorescent Sca-1 staining. Scale bars, 50µm. D, 
E. The graphs show the percentage of GFP-Sca-1
+
-VPC or Sca-1
+
 cells within the DAPI
+
 
cells in the neointima (white dotted line indicates internal elastin, the neointima area was 
surrounded by the line). Representative images and graphs shown as mean ± SEM of n=8 
mice/group. **P<0.01, ***P<0.001. WT, wild type. 
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Figure 6. Lack of CCL2 reduces neointima formation and inhibits Sca-1
+
 cells migration 
and differentiation into SMCs A. Animals were euthanized at indicated time points after 
injury, and the femoral arteries were fixed in 4% phosphate-buffered (pH=7.2) formaldehyde, 
embedded in paraffin, sectioned in 5 µm, and stained with hematoxylin–eosin. Scale bars, 
50µm. B. The ratio of neointima (the area between arrows) to media was quantified as shown 
in the graph. C, D. Vessel sections were also prepared for immunofluorescent α-SMA and 
CCR2 staining 2 weeks post wire injury (white dotted line indicates internal elastin, and the 
above is neointima area). Scale bars, 50µm.  E, F. Quantification of the percentage of 
positively stained cells within the neointima was shown in graphs as mean ± SEM of n=8 
mice/group. **P<0.01, ***P<0.001. WT, wild type. PBS, phosphate buffered saline. VPC, 
vascular progenitor cell. 
 
 
Figure 7. CCL2 released from peripheral tissue plays an important role in contribution 
of the neointima formation A. Using chimeric mice model, the CCL2 in peripheral blood of 
indicated mice was subjected to a CCL2 Quantikine ELISA kit. The vessels sections of 
indicated mice at various time points were stained with hematoxylin–eosin, and the neointima 
area (the area between arrows) was shown in the represented images (B) Scale bars, 50µm. , 
and quantified in the graphs (C) shown as mean ± SEM of n=5 mice/group. *p<0.05, 
**p<0.01, ***p<0.001. WT+CCL2
-/-
 BMT，wild type mice of which bone marrow was 
transplanted from CCL2
-/- 
mice. CCL2
-/-
+WT BMT, CCL2
-/-
 mice of which bone marrow was 
transplanted from wild type mice. 
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SUPPLEMENTAL MATERIAL AND METHODS 
 
Mice 
All procedures were performed according to protocols approved by the Institutional 
Committee for Use and Care of Laboratory Animals. The CCL2 deficient mice (B6.129S4-
Ccl2
tm1Rol
/J) and GFP mice (C57BL/6-Tg(UBC-GFP)30Scha/J) on the C57BL/6J background 
were purchased from The Jackson Laboratory (Bar Harbour, Maine, USA). C57BL/6J mice 
(as WT mice) were purchased from Harlan, UK. Genotyping for CCL2
+/-
 and CCL2
-/-
 mice 
was performed using standard PCR according to a protocol provided by The Jackson 
Laboratory. The following primers were used: oIMR7415 (CCL2
-/-
 forward) 5’- GCC AGA 
GGC CAC TTG TGT AG-3’, oIMR9219 (CCL2+/+ forward) 5’- TGA CAG TCC CCA GAG 
TCA CA’ and oIMR9220 (common reverse) 5’- TCA TTG GGA TCA TCT TGC TG -3’.  
 
 
Mouse vascular progenitor cell culture  
Mouse vascular progenitor cells were derived from the outgrowth of adventitial tissues of 
vein grafts as previously described[1]. Briefly, the vena cava from a C57BL/6J mouse was 
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isografted between two ends of the carotid artery of an isogenic mouse or GFP C57BL/6J 
mouse. After 2 weeks graft tissues were carefully harvested and cut into pieces and explanted 
on 0.04% gelatin (0.04% of 2% Solution Type B from Bovine Skin, Sigma)-coated flasks. 
Culture was in complete stem cell culture medium comprised of  Dulbecco's Modified Eagle's 
Medium (ATCC, Rockville, Massachusetts, USA) supplemented with 10% ES Cell Qualified 
Fetal Bovine Serum (EmbryoMax, Millipore), 10 ng/ml leukemia inhibitory factor, 0.1 mM 
β-mercaptoethanol, 100U/ml penicillin/streptomycin and 2mM L-glutamine(Life 
Technologies).  Graft tissues were incubated at 37℃，5% CO2 for 3 days. The cells that grew 
out from the graft tissue were dissociated from the flasks using 0.05% trypsin-EDTA (Life 
Technologies) and were passaged every other day at a 1 to 3 ratio.  
 
Isolation of clones and characterization  
Single cell clones were isolated by serial dilution of vascular progenitor cells, as described on 
the Corning Incorporated website[2]. Briefly, 96 wells (two 48-well plates) were labeled from 
rows A to H and columns 1 to 12. 200μl of culture medium was added to each of the wells 
except well A1. 400μl cell suspension was then added to A1, and 200μl was transferred from 
A1 to B1. These 1:2 dilutions were repeated down the column until well H1, discarding 
200μl from H1. 200μl was then transferred from the wells in the first column (A1 to H1) to 
those in the second column (A2 to H2). These 1:2 dilutions were repeated across the whole 
96 wells, discarding 200μl from each well in the last column. Plates were then incubated at 
37℃， in a 5% CO2 incubator. On the next day, wells that contained only a single cell were 
marked and medium was changed every other day. 7 to 10 days later, the single colony could 
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be sub-cultured successively into a single well of a 24-well plate, a 12-well plate, or a T25 
flask. The number of clones that were successfully expanded was recorded. Clones were 
characterized using conventional PCR and immunofluorescent staining.  
 
Mouse vascular smooth muscle cell culture 
Mouse vascular smooth muscle cells were isolated from the aortas of C57BL/6J mice as 
described previously[3]. In brief, the murine aortas were removed from the aortic arch to the 
thoracic aorta and washed within DMEM. The intima and inner two thirds of the media were 
carefully dissected from the aortas and cut into pieces, then placed onto a gelatin-coated 
(0.04%) plastic flask. The cells were cultured in Dulbecco's Modified Eagle's Medium (Life 
Technologies, Inc.) supplemented with 10% fetal bovine serum (Gibico 10270) and 100U/ml 
penicillin/streptomycin. Cells were incubated at 37°C in a humidified atmosphere of 5% CO2. 
The medium was changed every 2 days. The purity of SMCs was routinely confirmed by 
immunostaining with α-SMA, SM-22 α and SM-MHCII antibodies. Smooth muscle cell 
conditional medium was collected from the supernatant of serum free medium, in which cells 
had been cultured overnight, by centrifuging 1500rpm, 15mins, at 4℃. 
 
Antibodies 
Primary antibodies were mouse anti-Cdc42, mouse anti-Rac1 (Millipore 17-441 | 
Rac1/Cdc42 Activation Assay Kit), rabbit anti- Phospho-p38 MAPK (Thr180/Tyr182) (Cell 
signaling 4511), rabbit anti-p38 MAPK (Cell signaling 9212), rat anti-Sca-1/ Ly6A/E (abcam 
51317),  mouse anti-Actin, α-Smooth Muscle-Cy3 (α-SMA) (Sigma C6198), rabbit anti-
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calponin (abcam ab46794), rabbit anti-CCR2 (abcam ab21667), rabbit anti-vinculin (abcam 
ab73412), rabbit anti-paxillin (abcam ab32084) and goat anti-PECAM-1(Santa Cruz sc1506), 
goat anti-VE-cadherin (Santa Cruz sc-6458), mouse anti-CCL2 (R&D AF-479-SP), mouse 
anti-CXCL1 (R&D AF-453-SP). Secondary antibodies for immunostaining were anti-mouse 
Alexa Fluor 546, anti-rabbit Alexa Fluor 546 and anti-rat Alexa546 and were purchased from 
Invitrogen. Cells were also counterstained with Alexa Fluor
®
 488 Phalloidin (Life 
technologies A12379) and 10µg/ml 4', 6-diamidino-2-phenylindole (DAPI). Secondary 
antibodies for Western Blotting were purchased from Dako. 
 
Recombinant Proteins, Antagonists, siRNA and shRNA 
Recombinant Murine JE/CCL2 and Recombinant Murine CXCL1 were obtained from 
Peprotech and added to DMEM medium at indicated concentrations. CCR2 antagonist 
(C28H34F3N5O4S) and CXCR2 antagonist, Cpd-19 (C18H21N3O4) were purchased from 
Calbiochem. Rac1 inhibitor NSC23766 (C24H38Cl3N7) and Cdc42 inhibitor ML141 
(C22H21N3O3S) were purchased from Calbiochem. Rho Inhibitor I (CT04, active site is C3 
transferase) was purchased from Cytoskeleton. P38 inhibitor SB203580 (C12H16FN3OS), was 
purchased from Merck Millipore. CCL2 siRNA (m) and Control siRNA (fluorescein 
Conjuagate)-A were purchased from Santa Cruz Biotechnology. Silencer
®
 Select mouse 
CXCL1 siRNA and Negative Control siRNA was purchased from Ambion. The CCR2 and 
CXCR2 Mission shRNA Bacterial Glycerol Stocks were purchased from Sigma Aldrich. The 
shRNA Non-Targeting (NT) vector, SHC002 was used as a negative control.  
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Cell Sorting 
As described in previous studies[4], heterogeneous vascular progenitor cells which grew out 
from vein grafts were sorted by magnetic cell sorting kits (MACS) with anti-Sca-1 
immunomagnetic microbeads (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany). 
Briefly, the cells were incubated with the antibody-conjugated/coated microbeads at 4°C and 
then selected using a magnetic cell separator (Miltenyi Biotec). Sca-1 positive vascular 
progenitor cell populations were expanded for up to 5 population doublings. 
 
Immunofluorescence Staining 
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma) 
and blocked with 5% normal donkey serum (Dako) for 1 hour at room temperature. 
Incubation of cells with primary antibodies was performed at 4℃ overnight, followed by 
incubation with secondary antibodies (Corresponding fluorescent-conjugated IgG antibodies 
were used as secondary antibodies (Invitrogen)) for 45 mins at 37℃. Then cells were 
counterstained with DAPI (Sigma) for 5 mins at room temperature and mounted with 
fluorescent mounting media (Dako). Images were acquired using an Olympus IX81 
microscope and Volocity software (PerkinElmer). 
 
Transwell Chemotaxis Assay 
Migration assays were performed using transwell inserts with 8.0 µm pore membrane filters 
(Corning). Vascular progenitor cells were loaded onto the upper chamber at 5x10
4
 cells in 
serum free media, while the bottom chamber contained SMC conditional medium or serum 
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free medium with indicated concentrations of recombinant murine CCL2 or CXCL1. Serum 
free medium served as negative control. After an overnight incubation, non-migrating cells 
on the upper side of the filters were carefully washed and removed using a swab. Vascular 
progenitor cells on the underside of the membrane were fixed with 4% PFA for 10 mins 
followed by 0.1% crystal violet solution staining at room temperature for 15 mins. Data was 
expressed as the fold of migrated vascular progenitor cells compared to the control in 9 fields 
of each insert (at 20x). For experiments which involved inhibitors, vascular progenitor cells 
were pre-treated with the respective inhibitors before transferring to transwells.  
 
Scratch-wound Assay 
Vascular progenitor cells were seeded in a 12-well plate. Upon reaching complete 
confluency, a straight scratch was made using a pipette tip to stimulate a 'wound' through the 
middle of each well. The wells were gently washed with PBS to remove cell debris prior to 
treatment with SMC conditional medium or serum free medium with or without (control) 
recombinant murine CCL2 or CXCL1. After an overnight incubation, the migration of 
vascular progenitor cells into the “wound” area was quantified as the mean number of the 
cells which migrated into the “wound” in 5 random fields of each well using a phase contrast 
microscope(at 10x).  
 
Time-lapse Microscopy 
Cells were seeded onto 6-well plates and held with or without SMC conditioned media at 
37˚C and 5% CO2 on the stage of a fully motorized, multi-field time-lapse microscope 
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(Eclipse TE 2000-E; Nikon) with a charge-coupled device camera (ORCA; Hamamatsu 
Photonics). Bright-field images were acquired for 20 hours with pictures taken at 5-min 
intervals using the 10x objective. Images were acquired using Volocity software 
(PerkinElmer), and cells were tracked using ImageJ software (National Institute of Health). 
Analysis of cell speed and persistence was performed using the Chemotaxis plug in from 
Integrated BioDiagnostics.  
 
RT-PCR 
Total RNA was isolated from vascular progenitor cells using a QIAGEN RNeasy Mini kit 
according to the manufacturer’s instructions. 1 μg RNA was reverse transcribed into cDNA 
with random primers using the MMLV reverse transcriptase kit (Promega). PCR was carried 
out on 50ng cDNA to amplify the mouse CCL2 receptor CCR2 gene using primers:  
Forward 5'- TCCACTCTACTCCCTGGTATTC-3';  
Reverse 5' - TGGCCAAGTTGAGCAGATAG - 3'.  
The murine CXCL1 receptor CXCR2 gene primers:  
Forward 5’-TCTGGCCCTGCCCATCTTAATTCT-3’;  
Reverse 5’- AAAGTCTGAGGCAGGATACGCAGT -3’.  
The PCR products were analyzed on 2% agarose gels and assessed using a BioSpectrum AC 
Imaging System and Vision- WorksLS software. 
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Quantitative Real Time Polymerase Chain Reaction (qPCR) 
The methods described above were used for RNA extraction and cDNA reverse transcription. 
Real time RT-PCR was performed using 20ng of cDNA per sample with a SYBR Green 
Master Mix in a 20 μl reaction. Ct values were measured using the Eppendorf Mastercycler 
ep Realplex and GAPDH was used as an endogenous control to normalize the amounts of 
RNA in each sample. The sequences of chemokine CCL2 primer sets are: 
Forward 5’-AGTAGGCTGGAGAGCTACAA-3’,  
Reverse 5’-GTATGTCTGGACCCATTCCTTC-3’, 
The sequences of chemokine CXCL1 primer sets are: 
Forward 5’-GCTGGGATTCACCTCAAGAA-3’,  
Reverse 5’-TGGCTATGACTTCGGTTTGG-3’, 
 
Western Blot Analysis 
Harvested vascular progenitor cells were lysed with lysis buffer (25 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA pH 8.0, 1%Triton X-100 plus protease inhibitors(Roche), 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche))  and proteins were sequentially 
measured using the Bradford method. 40 μg of protein lysate was applied to 4-12% Bis-Tris 
Protein gels (NuPAPE, Novex) before being transferred to a nitrocellulose membrane 
(Amersham Biosciences), followed by a standard western blotting procedure.  
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CCL2 and CXCL1 gene knockdown 
Gene suppression of CCL2 or/and CXCL1 in mouse smooth muscle cells was carried out 
using the Basic SMC Nucleofector® Kit (Lonza) with CCL2 siRNA (Santa Cruz 
Biotechnology)  or/and CXCL1 siRNA (ambion) as the manufacturers described. Control 
siRNA (FITC Conjugate)-A (Santa Cruz Biotechnology) or Negative control siRNA 
(ambion) was used as a negative control. After gene ablation, the level of down regulation of 
total RNA or proteins was assessed using real time qPCR or ELISA analysis, respectively. 
 
CCR2 and CXCR2 gene knockdown 
Gene ablation of CCR2 or/and CXCR2 was carried out using short hairpin RNA (shRNA) 
lentiviral plasmid transfer as previously described[5, 6].  A non-targeting vector (SHC002) 
was used as a negative control. Total gene and protein levels were assessed using qPCR and 
flow cytometry analysis after gene ablation. 
 
FACS analysis 
Vascular progenitor cells were treated with/without SMC conditioned media, and incubated 
with antibodies (mouse anti-CXCR2 PE-conjugated antibody (R&D), rabbit anti-CCR2 
(abcam) or mouse IgG PE (BD biosciences) for 30 mins on ice before analysis by FACS in 
order to test the change of CXCR2 or CCR2 receptor expression levels. Data analysis was 
carried out using FlowJo software. 
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Femoral artery injury 
Mice were anesthetized with (ketamine and medetomidine hydrochloride) and the surgical 
procedure was similar to that described previously[7]. Both of the femoral arteries of each 
mouse were injured by inserting a 0.25 mm guide wire (CROSS-IT 100XT, HI-TORQUE) 4-
mm length from one of the distal muscle branches to femoral artery.  One artery was seeded 
with Sca-1
+
 vascular progenitor cells (1x10
6
 cells) within 25 μl Matrigel® Basement 
Membrane Matrix (Corning), and the other injured artery served as a control. Arteries were 
harvested at day 7 or day 14 and used to prepare frozen or paraffin sections. 
For the siRNA knockdown experiments in vivo, either 5 μg CXCL1 or Negative Control 
siRNA dissolved in 30% pluronic Gel-127 was perivascularly delivered to the femoral 
arteries immediately after wire injury. After 3 days, GFP-Sca1
+
 vascular progenitor cells 
(1x10
6
 cells) within 25 μl Matrigel® Basement Membrane Matrix were seeded on the 
adventitia of both siRNA treated femoral arteries. Arteries were harvested for either RNA 
extraction or en face staining after a further 72 hours. 
 
En face staining 
En face staining was used for quantification of reendothelializaiton. Briefly, femoral arteries 
were fixed with 4% paraformaldehyde, then permeabilized and blocked with a solution of 0.5% 
Triton X-100 and 5% donkey serum in PBS. Incubation of vessels with primary antibodies 
was performed at 4℃ overnight, followed by incubation with corresponding fluorescent-
conjugated secondary antibodies (Invitrogen) or IgG as negative control for 2 hours at room 
temperature. Then nuclei were stained with DAPI for 5 mins at room temperature before 
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vessel segments were mounted with the endothelium face up on a glass slide.  Images were 
taken using a Leica SP5 confocal microscope and assessed using LAS AF lite software  
 
 
Creation of chimeric mice  
The procedure used for creating chimeric mice was similar to previously described[8]. In 
brief, bone marrow transplantation was carried out on the CCL2
+/+
 mice and CCL2
-/-
 mice 
separately. Bone marrow cells were obtained from the femurs and tibias of either CCL2
+/+
 or 
CCL2
-/-
 mice (donors) and injected (1x10
7
cells in 0.2ml) into the tail veins of the 6-8 week 
old CCL2
-/-
 mice or CCL2
+/+
 mice (recipients) which received lethal irradiation (950 Rads) 
before. Femoral artery injury was performed 3 weeks after bone marrow transplantation.   
  
Rac1/Cdc42 GTPase activation assay  
The activation assay of GTP-bound Rac1/Cdc42 was carried out according to the 
manufacturer’s instructions (Rac1/Cdc42 Activation Assay Kit (Upstate, Millipore)). In 
addition to the solutions from the kit, PAK-PBD beads from cytoskeleton, Protease Inhibitor 
Cocktail (Sigma-Aldrich) and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche) 
were also used. Briefly, cells were stimulated with the indicated treatments then placed on ice 
and scraped within 1x MLB (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 10 
mM MgCl2, 1mM EDTA and 2% glycerol), and samples were centrifuged for 10 mins. 
Aliquots were collected for total Rac1 or Cdc42 (input) and GTPγS (positive) and GDP 
(negative) control analysis. Lysates were rotated with 20µg of PAK-PBD agarose beads at 
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4 °C for 1 hour. The agarose pellet was washed twice and re-suspended in 25µl SDS sample 
buffer. Samples were separated by 4–12% Bis-Tris gels, transferred to nitrocellulose 
membranes, and blotted for Rac1 or Cdc42 antibodies (Upstate, Millipore). 
 
RT
2
 Profiler
TM
 PCR Arrays for Mouse Chemokines and Receptors   
Total RNA (0.5 μg) (extracted from either mouse peritoneal macrophages, vascular smooth 
muscle cells, Sca-1
+
 vascular progenitor cells or one cloned colony of vascular progenitor 
cells cultured in vitro) was reverse transcribed to cDNA and used to screen mouse chemokine 
receptors using quantitative real-time PCR arrays according to the manufacturer's instructions 
(Qiagen PAMM-022Z). Reactions were performed in an Eppendorf
®
 Mastercycler
®
 ep 
Realplex model 4S. Acquired data were analyzed using the 2
-(averageΔCT)
 method to determine 
the expression level of each transcript normalized to the expression level of housekeeping 
gene controls.  
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Supplement Figure Legend 
 
Figure 1. Isolation of clones and characterization. Single cells were obtained by serial 
dilution, approximately 3% to 5% of cells formed clones that could be gradually expanded. A, 
Two cells (in red circles) from the same clone colony are shown in the represented image. B, 
C, D. Clone colonies were characterized using immunofluorescence staining for progenitor 
cell marker (Sca-1), SMC markers (SM-MHCII, Calponin) or endothelial cell markers (CD31，
CD144).  Scale bars, 100µm. SM-MHCII, smooth muscle cell myosin heavy chain class II.  
 
Figure 2. SMC-CM has no effect on VPCs proliferation and differentiation.  
A. Evaluation of vascular progenitor cell proliferation in response to SMC conditioned 
medium, CXCL1or CCL2 treatments compared to an untreated control after 18 hours was by 
BrdU incorporation assay. B, C, D, E. Total RNA from vascular progenitor cells was 
harvested and subjected to qPCR for analysis of SMC markers (α-SMA, SM-MHCII), 
endothelial cells marker (CD31) and progenitor cells marker (Sca-1) expression. All graphs 
are shown as mean ± SEM of n=3. ns, P>0.05. ctrl, control, serum free medium. CM, SMC 
conditioned medium.  
 
Figure 3. SMC conditioned medium increases paxillin, vinculin and phosphorylated 
FAK expression.  A. Vascular progenitor cells were treated with SMC conditioned medium 
for 5 minutes before immunofluorescence staining for paxillin, vinculin and phosphorylated 
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FAK. Scale bars, 25µm. ctrl, control, serum free medium. CM, SMC conditioned medium. p-
FAK, phosphorylated FAK. 
 
Figure 4. CCL5 has no effect on VPCs migration. A. The transwell assay was performed on 
vascular progenitor cells that migrated toward either serum free medium (control) or serum 
free media containing murine recombinant CCL5 (5ng/ml, 50ng/ml). Transwell migration 
assays show VPCs migrated towards serum free medium with or without mouse recombinant 
CCL5 (5ng/ml, 50ng/ml). Scale bars, 100µm.  B. The graph is shown as mean ± SEM of n=3. 
ns, P>0.05. 
 
Figure 5. The effects of CCL2 and CXCL1 are neither cumulative nor redundant in 
mediating VPC migration. A-D. The SMC conditioned medium was treated with either 
neutralizing antibodies for CCL2 and/or CXCL1 or the relevant control IgG for 1 hour at 37℃ 
before pull-down of chemokines combined with antibodies using protein G beads. The 
supernatant was collected and used to measure the concentrations of CCL2 (A) and CXCL1 
(B) using corresponding ELISA kits. The transwell assay (C, D) was performed on VPCs that 
migrated toward SMC conditioned medium (positive control) or SMC conditioned medium 
after depletion of chemokines with IgG, CCL2 and/or CXCL1 neutralizing antibodies pull 
down. Scale bars, 100µm. E, F. The VPCs were treated with either CXCL1 or CCL2 at 
indicated concentrations overnight followed by measurement of concentrations of CCL2 and 
CXCL1 using ELISA. The graphs are shown as mean±SEM of n=3, **p<0.01, ***p<0.001, 
ns, P>0.05. 
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Figure 6. Antagonists of CCR2 or CXCR2 inhibited SMC-mediated VPC migration via 
the p38 signaling pathway. A, B. The transwell assay was performed on vascular progenitor 
cells that were pre-treated with DMSO, antagonists of CCR2 or CXCR2 1 hour before 
migrating toward SMC conditioned medium. Scale bars, 100µm. C, D. Western blotting was 
performed on vascular progenitor cell lysates (40 μg per condition) to detect phosphorylation 
of p38 and total p38. Untreated cells served as the control. The quantification is represented 
as mean ± SEM of n=3. ***p<0.001.  ctrl, control, serum free medium. CM, SMC 
conditioned medium. DMSO, Dimethyl sulfoxide.  CCR2 Anta, CCR2 antagonist. CXCR2 
Anta, CXCR2 antagonist. 
 
Figure 7. The RhoA signalling pathway is not involved in the SMC induced VPCs 
migration. A. After pre-treatment with either vehicle or C3 transferase (2µg/ml) for 2 hours, 
VPC were stimulated with SMC conditioned medium or recombinant CCL2 or CXCL1 
before cell lysates were harvested for western blotting to detect the p-p38 and t-p38. B. The 
transwell assay was performed on VPCs that were pre-treated with either vehicle or C3 
transferase (an inhibitor of RhoA) (2µg/ml) for 2 hours before migration toward either SMC 
conditioned medium or recombinant CCL2 or CXCL1. Scale bars, 100µm. Quantification is 
represented as mean ± SEM of n=3.  ns, P>0.05. CM, SMC conditioned medium. vehicle, 
sterile distilled water. 
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Figure 8. CCL2 and CXCL1 are expressed on wire-injured vessels in vivo. Femoral 
arteries of C57BL/6J mice were harvested after wire injury or from uninjured animals. Frozen 
sections of intact vessels or vessels 6 hours or 2 weeks after wire injury were co-stained with 
immunofluorescent markers either CCL2 (A, B, C) or CXCL1(D, E, F) and α-SMA. n=4 
mice/group. Scale bars, 50µm. 
 
Figure 9. Identify the CCL2
-/-
 mouse genotype and CCL2 level in the peripheral blood. 
A. To expand CCL2
-/-
 mice number, CCL2
-/-
 mice were crossed with CCL2
+/+
. A piece of ear 
tissue from each mouse was used to genotype offspring. The image shows a heterozygote 
(CCL2
+/-
) with bands at 287bp and 179bp and a mutant (CCL2
-/-
) with only one band at 
179bp. B. Peripheral blood was collected from  the vena cava before euthanasia of WT or 
CCL2
-/-
 mice and CCL2 level was measured using a murine CCL2 Quantikine ELISA kit 
from serum of each sample. The graph is shown as mean ± SEM of n=11 mice/group, 
***p<0.001.  
 
Figure 10. Lack of CCL2 inhibits Sca-1
+
 vascular progenitor cell migration in vivo.   
A. Sca-1
+
 vascular progenitor cells (1x10
6
), which were labeled with Q-tracker to locate them 
as they migrated, were seeded in the adventitia of each injured femoral artery. 72hrs post 
injury, the vessels were harvested.   En face staining shows that cells migrated to the intima 
side of the vessels of WT and CCL2
-/-
 mice. Scale bars, 25µm. B. The ratio of the 
fluorescence intensity (Qtracker:DAPI) is represented in the  graphs. The graph is shown as 
mean ± SEM of n=8 mice/group, **p<0.01. 
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Figure 11. Characterization of cells in the neointima. A. Femoral arteries without seeding 
VPC in the adventitia were harvested 2 weeks after wire injury from C57BL/6J mice and 
stained with Sca-1 and α-SMA (white dotted line indicates internal elastin, and the circled 
part is neointima area).  Scale bars, 50µm.  B. The ratios of positively stained cells with each 
marker in the neointima area are quantified and shown in the graph.  
 
Figure 12. CXCL1 can induce Sca-1 positive cell migration in vivo. Using a matrigel plug 
assay, matrigel including PBS or mouse recombinant CXCL1 was injected subcutaneously 
into C57BL/6J mice. The matrigel plugs were harvested 2 weeks later and the frozen sections 
were stained with either (A) hematoxylin–eosin (Scale bars, 100µm)  or (B) 
immunofluorescent markers (Sca-1, CD31, α-SMA) (Scale bars, 100µm). The numbers of 
cells migrated into the matrigel (quantification from bottom images in A) or positively 
stained with each marker are quantified and shown in the graphs. Graphs are shown as mean
±SEM of n=8, **P<0.01. vehicle, sterile distilled water. 
 
Figure 13. CXCL1 small interfering RNA inhibits Sca-1
+
 cells migration in vivo.  
A, Quantification of CXCL1 mRNA level 6 days after perivascular application of CXCL1 or 
negative control siRNA dissolved in pluronic gel by qPCR. Graphs are shown as mean±
SEM of n=4, **P<0.01. B. Representative images of En face staining show the cells migrated 
to the intima side of the vessels 72hrs post seeding GFP-Sca-1
+
-VPC (1x10
6
) in the adventitia 
of femoral arteries treated with CXCL1 or control siRNA. Scale bars, 25µm. 
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Figure 14. Schematic illustration of the role of CCL2 and CXCL1 released from SMCs 
in enhancing VPCs chemotaxis. SMCs release CCL2 and CXCL1 into the medium. When 
VPCs are treated with this SMC-CM, these chemokines bind to their corresponding receptors 
CCR2 and CXCR2 on the VPCs. The GTPase Rac1 and Cdc42 become activated and then 
p38 is phosphorylated via Rac1, finally leading to increased VPC migration. SMC-CM also 
induces expression of cytoskeleton related proteins paxillin, vinculin and phosphorylated 
FAK, which may also activate the Rac1 or Cdc42 signaling pathway. 
 
Graphical Abstract. Schematic illustration of the role of CCL2 and CXCL1 released from 
SMCs in enhancing VPCs chemotaxis. SMCs release CCL2 and CXCL1 into the medium. 
When VPCs are treated with this SMC conditioned medium, these chemokines bind to their 
corresponding receptors CCR2 and CXCR2 on the VPCs. The GTPase Rac1 become 
activated and then p38 is phosphorylated via Rac1, finally leading to increased VPC 
migration. SMC conditioned medium also induces expression of cytoskeleton related proteins 
paxillin, vinculin and phosphorylated FAK, which may also activate the Rac1 signaling 
pathway. 
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Supplemental Table 1 
Gene expressions of chemokines and chemotatic cytokines in different cell lines 
(2
-avgΔct
)(x10
-4
) 
Refseq Symbol Description SMC Sca-1
+ 
VPC clone 
NM_011329 Ccl1 Chemokine (C-C motif) ligand 1 7.16 0.83 0.8 
NM_011330 Ccl11 Chemokine (C-C motif) ligand 11 7.16 15.81 3.14 
NM_011331 Ccl12 Chemokine (C-C motif) ligand 12 560.56 0.42 0.46 
NM_011332 Ccl17 Chemokine (C-C motif) ligand 17 175.55 2.95 2.05 
NM_011888 Ccl19 Chemokine (C-C motif) ligand 19 7.16 1.6 1.6 
NM_011333 Ccl2 Chemokine (C-C motif) ligand 2 11916.83 7981.14 1677.83 
NM_016960 Ccl20 Chemokine (C-C motif) ligand 20 309.91 1.21 0.67 
NM_009137 Ccl22 Chemokine (C-C motif) ligand 22 7.16 0.45 0.58 
NM_019577 Ccl24 Chemokine (C-C motif) ligand 24 7.16 0.47 0.61 
NM_009138 Ccl25 Chemokine (C-C motif) ligand 25 100.48 116.09 73.64 
NM_001013412 Ccl26 Chemokine (C-C motif) ligand 26 7.16 0.62 1.15 
NM_020279 Ccl28 Chemokine (C-C motif) ligand 28 7.16 6.88 7.42 
NM_011337 Ccl3 Chemokine (C-C motif) ligand 3 600.79 0.42 0.5 
NM_013652 Ccl4 Chemokine (C-C motif) ligand 4 191.44 1.17 0.79 
NM_013653 Ccl5 Chemokine (C-C motif) ligand 5 26.1 263.02 38.74 
NM_009139 Ccl6 Chemokine (C-C motif) ligand 6 617.68 6.35 0.89 
NM_013654 Ccl7 Chemokine (C-C motif) ligand 7 25105.44 13329.91 4055.64 
NM_021443 Ccl8 Chemokine (C-C motif) ligand 8 34.43 417.52 7.98 
NM_011338 Ccl9 Chemokine (C-C motif) ligand 9 156.03 9.6 3.76 
NM_027022 Cmtm2a CKLF-like MARVEL transmembrane domain containing 2A 7.16 0.42 0.46 
NM_024217 Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 1464.01 1350.28 1536.8 
NM_153582 Cmtm4 CKLF-like MARVEL transmembrane domain containing 4 193.44 91.29 56.33 
NM_026066 Cmtm5 CKLF-like MARVEL transmembrane domain containing 5 7.26 2.62 0.49 
2 
 
NM_026036 Cmtm6 CKLF-like MARVEL transmembrane domain containing 6 158.21 52.8 78.02 
NM_009142 Cx3cl1 Chemokine (C-X3-C motif) ligand 1 82.47 111.61 84.59 
NM_008176 Cxcl1 Chemokine (C-X-C motif) ligand 1 5598.06 4179.3 965.89 
NM_021274 Cxcl10 Chemokine (C-X-C motif) ligand 10 24.1 95.39 8.59 
NM_019494 Cxcl11 Chemokine (C-X-C motif) ligand 11 7.16 1.13 0.46 
NM_021704 Cxcl12 Chemokine (C-X-C motif) ligand 12 1222.58 3211.53 10752.46 
NM_018866 Cxcl13 Chemokine (C-X-C motif) ligand 13 7.16 0.42 0.46 
NM_019568 Cxcl14 Chemokine (C-X-C motif) ligand 14 233.25 8.33 5.32 
NM_011339 Cxcl15 Chemokine (C-X-C motif) ligand 15 9.82 44.19 450.6 
NM_023158 Cxcl16 Chemokine (C-X-C motif) ligand 16 264.24 249.41 175.14 
NM_009140 Cxcl2 Chemokine (C-X-C motif) ligand 2 133.04 3.22 3.83 
NM_203320 Cxcl3 Chemokine (C-X-C motif) ligand 3 29.56 0.54 0.75 
NM_009141 Cxcl5 Chemokine (C-X-C motif) ligand 5 1351.84 22058.48 34058.15 
NM_008599 Cxcl9 Chemokine (C-X-C motif) ligand 9 8.4 2.33 0.46 
NM_008337 Ifng Interferon gamma 7.16 0.42 0.46 
NM_010551 Il16 Interleukin 16 7.57 95.17 231.64 
NM_008361 Il1b Interleukin 1 beta 34.79 0.74 1.02 
NM_021283 Il4 Interleukin 4 7.16 0.54 0.63 
NM_031168 Il6 Interleukin 6 183 2128.63 366.85 
NM_019932 Pf4 Platelet factor 4 149.16 1.26 2.99 
NM_023785 Ppbp Pro-platelet basic protein 7.16 2.65 2.72 
NM_011577 Tgfb1 Transforming growth factor, beta 1 386.87 221.69 210.7 
NM_013693 Tnf Tumor necrosis factor 42.1 0.42 0.46 
NM_008510 Xcl1 Chemokine (C motif) ligand 1 7.16 0.42 0.46 
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Supplemental Table 2 
Gene expressions of chemokines and chemotatic cytokines receptors  in different cell lines  
(2
-avgΔct
 )(x10
-4
) 
Refseq Symbol Description SMC Sca-1
+
 VPC clone 
NM_007577 C5ar1 Complement component 5a receptor 1 118.66 0.42 0.46 
NM_021609 Ackr2 Chemokine binding protein 2 7.16 0.65 0.59 
NM_009912 Ccr1 Chemokine (C-C motif) receptor 1 30.5 3.99 2.13 
NM_007721 Ccr10 Chemokine (C-C motif) receptor 10 7.16 3.11 6.23 
NM_007718 Ccr1l1 Chemokine (C-C motif) receptor 1-like 1 7.16 0.42 0.46 
NM_009915 Ccr2 Chemokine (C-C motif) receptor 2 7.29 0.42 0.51 
NM_009914 Ccr3 Chemokine (C-C motif) receptor 3 45.75 0.42 0.46 
NM_009916 Ccr4 Chemokine (C-C motif) receptor 4 7.16 0.42 0.46 
NM_009917 Ccr5 Chemokine (C-C motif) receptor 5 126.74 0.42 0.47 
NM_009835 Ccr6 Chemokine (C-C motif) receptor 6 7.16 0.42 0.48 
NM_007719 Ccr7 Chemokine (C-C motif) receptor 7 7.16 0.45 0.78 
NM_007720 Ccr8 Chemokine (C-C motif) receptor 8 7.16 0.42 0.46 
NM_009913 Ccr9 Chemokine (C-C motif) receptor 9 7.16 0.88 1.03 
NM_145700 Ackr4 Chemokine (C-C motif) receptor-like 1 7.16 2.02 3.72 
NM_017466 Ccrl2 Chemokine (C-C motif) receptor-like 2 7.16 4.99 10.26 
NM_008153 Cmklr1 Chemokine-like receptor 1 29.67 0.42 0.72 
NM_009987 Cx3cr1 Chemokine (C-X3-C) receptor 1 80.77 0.42 0.46 
NM_178241 Cxcr1 Chemokine (C-X-C motif) receptor 1 7.16 0.42 0.46 
NM_009909 Cxcr2 Chemokine (C-X-C motif) receptor 2 7.16 0.42 0.46 
NM_009910 Cxcr3 Chemokine (C-X-C motif) receptor 3 7.16 0.42 0.46 
NM_009911 Cxcr4 Chemokine (C-X-C motif) receptor 4 63.59 0.59 0.46 
NM_007551 Cxcr5 Chemokine (C-X-C motif) receptor 5 7.16 0.42 0.46 
NM_030712 Cxcr6 Chemokine (C-X-C motif) receptor 6 7.16 1.31 9.02 
NM_007722 Ackr3 Chemokine (C-X-C motif) receptor 7 145.08 795.5 779.13 
4 
 
NM_010045 Darc Duffy blood group, chemokine receptor 9.42 0.48 0.48 
NM_013521 Fpr1 Formyl peptide receptor 1 33.72 0.91 1.16 
NM_001025381 Gpr17 G protein-coupled receptor 17 7.16 0.87 1.24 
NM_011798 Xcr1 Chemokine (C motif) receptor 1 7.16 0.54 0.46 
 
  
5 
 
Supplemental Figure 3 
Gene expressions of other chemotaxis  in different cell lines  
(2
-avgΔct
)(x10
-4
) 
Refseq Symbol Description SMC Sca-1
+
VPC clone 
NM_010431 Hif1a Hypoxia inducible factor 1, alpha subunit 1209.93 2109.05 3514.36 
NM_008401 Itgam Integrin alpha M 89 0.42 0.46 
NM_008404 Itgb2 Integrin beta 2 226.87 15.13 17.62 
NM_011949 Mapk1 Mitogen-activated protein kinase 1 910.62 526.05 694.12 
NM_011951 Mapk14 Mitogen-activated protein kinase 14 159.87 191.66 208.76 
NM_178804 Slit2 Slit homolog 2 (Drosophila) 1105.68 276.74 276.1 
NM_011905 Tlr2 Toll-like receptor 2 59.33 61.21 34.59 
NM_021297 Tlr4 Toll-like receptor 4 50.76 100.13 91.92 
NM_138302 Tymp Thymidine phosphorylase 7.16 0.73 0.55 
 
 
